259 related articles for article (PubMed ID: 21177476)
1. The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.
Khroyan TV; Polgar WE; Cami-Kobeci G; Husbands SM; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Mar; 336(3):952-61. PubMed ID: 21177476
[TBL] [Abstract][Full Text] [Related]
2. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
3. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
4. Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.
Flynn SM; Epperly PM; Davenport AT; Cami-Kobeci G; Husbands SM; Ko MC; Czoty PW
Neuropsychopharmacology; 2019 Jul; 44(8):1476-1484. PubMed ID: 30970376
[TBL] [Abstract][Full Text] [Related]
5. Research progress on the potential novel analgesic BU08028.
Wang Y; Qin D; Guo Z; Shi F; Cannella N; Ciccocioppo R; Li H
Eur J Pharmacol; 2022 Jan; 914():174678. PubMed ID: 34875275
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
[TBL] [Abstract][Full Text] [Related]
7. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832
[TBL] [Abstract][Full Text] [Related]
8. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.
Khroyan TV; Wu J; Polgar WE; Cami-Kobeci G; Fotaki N; Husbands SM; Toll L
Br J Pharmacol; 2015 Jan; 172(2):668-80. PubMed ID: 24903063
[TBL] [Abstract][Full Text] [Related]
9. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.
Khroyan TV; Zaveri NT; Polgar WE; Orduna J; Olsen C; Jiang F; Toll L
J Pharmacol Exp Ther; 2007 Feb; 320(2):934-43. PubMed ID: 17132815
[TBL] [Abstract][Full Text] [Related]
10. Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.
Cami-Kobeci G; Polgar WE; Khroyan TV; Toll L; Husbands SM
J Med Chem; 2011 Oct; 54(19):6531-7. PubMed ID: 21866885
[TBL] [Abstract][Full Text] [Related]
11. Activities of mixed NOP and mu-opioid receptor ligands.
Spagnolo B; Calo G; Polgar WE; Jiang F; Olsen CM; Berzetei-Gurske I; Khroyan TV; Husbands SM; Lewis JW; Toll L; Zaveri NT
Br J Pharmacol; 2008 Feb; 153(3):609-19. PubMed ID: 18059322
[TBL] [Abstract][Full Text] [Related]
12. A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.
Zaveri NT; Marquez PV; Meyer ME; Polgar WE; Hamid A; Lutfy K
Alcohol Clin Exp Res; 2018 Feb; 42(2):461-471. PubMed ID: 29215139
[TBL] [Abstract][Full Text] [Related]
13. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
Zaveri NT
Curr Top Med Chem; 2011; 11(9):1151-6. PubMed ID: 21050175
[TBL] [Abstract][Full Text] [Related]
14. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
Cremeans CM; Gruley E; Kyle DJ; Ko MC
J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
[TBL] [Abstract][Full Text] [Related]
15. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
Kiguchi N; Ding H; Kishioka S; Ko MC
Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033
[TBL] [Abstract][Full Text] [Related]
16. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
Kiguchi N; Kishioka S; Ko MC
Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
[TBL] [Abstract][Full Text] [Related]
19. Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.
Cornelissen JC; Steele FF; Tenney RD; Obeng S; Rice KC; Zhang Y; Banks ML
Eur J Pharmacol; 2019 Feb; 844():175-182. PubMed ID: 30552903
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.
Kiguchi N; Ding H; Ko MC
J Neurosci Res; 2022 Jan; 100(1):191-202. PubMed ID: 32255240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]